Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Other EventsItem 8.01 Other Events.
On April 26, 2017, Syros Pharmaceuticals, Inc., a Delaware corporation (the “Company”), issued a press release announcing the closing of a previously announced private placement of 2,592,591 shares of its common stock, $0.001 par value per share, at a per share cash purchase price of $13.50. The private placement will result in gross proceeds of approximately $35,000,000 to the Company, prior to the deduction of fees and operating expenses. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
See the Exhibit Index attached hereto.
About Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Recent Trading Information
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) closed its last trading session up +0.67 at 16.21 with 15,911 shares trading hands.
An ad to help with our costs